Clinical Trial Update: Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing panitumumab plus pemetrexed and cisplatin (PemCisP) with pemetrexed and cisplatin (PemCis) as first-line treatment for non-small cell lu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Panitumumab (panitumumab)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: WiSP Wissenschaftlicher Service Pharma GmbH | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: SUSPENDED